Clinical trials: Cholangiocarcinoma Cancer
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT01313377
- Testing
- gemcitabine hydrochloride, oxaliplatin, clinical observation
- Where
- 37 sites in France
- Volunteers
- 190 people
- Sponsor
- UNICANCER
Intrahepatic Cholangiocarcinoma
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
The study trial is a open-label, single-arm, multicenter phase II trial investigating the combined treatment of atezolizumab and derazantinib in patients with advanced intrahepatic cholangiocarcinoma with FGFR2…
- Trial name
- NCT05174650
- Testing
- Atezolizumab, Derazantinib
- Where
- 17 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Cholangiocarcinoma, Intrahepatic, Recurrence Cholangiocarcinoma
Surgery for Recurrent Intrahepatic Cholangiocarcinoma
The investigators retrospectively reviewed the participants suffering from recurrent intrahepatic cholangiocarcinoma after curative resection and aimed to explore the predictive factors for recurrence and clarify the potential…
- Conditions
- Cholangiocarcinoma, Intrahepatic, Recurrence Cholangiocarcinoma, Re-hepatectomy
- Trial name
- NCT04072250
- Testing
- hepatectomy
- Where
- Taiwan
- Volunteers
- 216 people
- Sponsor
- Chang Gung Memorial Hospital
Cholangiocarcinoma
Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib
Chart Review on Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer Center with a combination of irinotecan, capecitabine and celecoxib.
- Trial name
- NCT00320918
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of New Mexico
Ampulla of Vater Adenocarcinoma, Gallbladder Adenocarcinoma
ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer
This phase I trial studies the side effects and best dose of ADH-1 when given together with gemcitabine hydrochloride and cisplatin in treating patients with pancreatic or biliary tract cancer that has spread from where it…
- Conditions
- Ampulla of Vater Adenocarcinoma, Gallbladder Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT01825603
- Testing
- ADH-1, Cisplatin, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Nebraska
Biliary Tract Cancer, Cholangiocarcinoma
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
The study to evaluate M7824 monotherapy in participants with advanced or metastatic biliary tract cancer (BTC) who failed or were intolerant to first-line (1L) chemotherapy.
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- NCT03833661
- Testing
- M7824
- Where
- 33 sites in United States, China and 7 more
- Volunteers
- 159 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Perihilar Cholangiocarcinoma, Klatskin Tumor
Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma
This is multicentric, single-arm, observational, investigator-drive study investigating the efficacy of liver transplantation after successful downstaging/disease control of unresectable perihilar cholangiocarcinoma using…
- Trial name
- pCOLA (NCT06986486)
- Where
- Italy
- Volunteers
- 8 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Portal Vein Occlusion, Cholangiocarcinoma, Perihilar
Portal Vein Embolization Using Coils Plus TAGM vs Multiple Coils for Patients With Perihilar Cholangiocarcinoma or Hepatocellular Carcinoma
The aim of this study is to investigate the differences of safety and liver hypertrophy between portal vein embolization (PVE) using coils plus tris-acryl gelatin microspheres (TAGM) and multiple coils in patients with perihilar…
- Conditions
- Portal Vein Occlusion, Cholangiocarcinoma, Perihilar, Hepatocellular Carcinoma, Liver; Hypertrophy, Acute
- Trial name
- NCT04386772
- Testing
- PVE with coils plus TAGM, PVE with multiple coils
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Cholangiocarcinoma, Biliary Tract Cancer (BTC)
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma
To investigate the efficacy and tolerability of neoadjuvant tislelizumab, gemcitabine, cisplatin and S-1 (TisGCS) in patients with resectable high-risk iCCA.
- Trial name
- TisGCS for BTC (NCT06903273)
- Testing
- Tislelizumab
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- National Cheng-Kung University Hospital
Pancreatic Carcinoma Stage II, Cholangiocarcinoma Resectable
Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients
This is a phase I/II study which intends to characterize the safety, tolerability, and preliminary efficacy of Allogeneic Magicell-NK infusion in PDA or cholangiocarcinoma patients after surgery.
- Trial name
- NCT06730009
- Testing
- SLOG + Allogeneic NK cell, SLOG chemotherapy
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- Medigen Biotechnology Corporation
Intrahepatic Cholangiocarcinoma
Conventional or Unconventional Lymph Node Dissection During Resection of Intrahepatic Cholangiocarcinoma
The aim of this study is to compare the surgical outcomes of conventional lymph node dissection with unconventional lymph node dissection during resection of Intrahepatic cholangiocarcinoma.
- Trial name
- NCT02526771
- Testing
- conventional lymph node dissection, unconventional lymph node dissection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Liver Metastases, Hepatocellular Carcinoma
Irreversible Electroporation of Unresectable Liver Tumors
The aim of this study is to evaluate the safety and feasibility of curative intended irreversible electroporation (IRE) in the treatment of liver tumors neighboring major vessels or bile ducts.
- Conditions
- Liver Metastases, Hepatocellular Carcinoma, Bile Duct Cancer
- Trial name
- NCT04404647
- Testing
- Irreversible electroporation
- Where
- Denmark
- Sponsor
- Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery
Pancreas Cancer, Pancreatic Cancer
Quebec Pancreas Cancer Study
The Quebec Pancreas Cancer Study is a prospective clinic-based study consisting of clinical, family history and epidemiologic data, with accompanying biospecimens, from patients diagnosed with either pancreas cancer, a related…
- Conditions
- Pancreas Cancer, Pancreatic Cancer, Pancreas Neoplasm, Pancreas Cyst
- Trial name
- QPCS (NCT04104230)
- Where
- Canada
- Volunteers
- 2,000 people
- Sponsor
- George Zogopoulos
Solid Tumor, Glioma
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
The purpose of this study is to evaluate the safety, pharmacokinetics, and clinical activity of enasidenib in adults with advanced solid tumors, including glioma, or with angioimmunoblastic T-cell lymphoma (AITL), with an…
- Conditions
- Solid Tumor, Glioma, Angioimmunoblastic T-cell Lymphoma, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT02273739
- Testing
- Enasidenib
- Where
- 12 sites in United States, France
- Volunteers
- 21 people
- Sponsor
- Celgene
Biliary Tract Cancer, Cholangiocarcinoma
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
- Trial name
- NCT05506943
- Testing
- CTX-009, Paclitaxel
- Where
- 34 sites in United States
- Volunteers
- 168 people
- Sponsor
- Compass Therapeutics
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT00544193
- Testing
- gemcitabine hydrochloride, polymerase chain reaction, immunohistochemistry staining method
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Intrahepatic Cholangiocarcinoma (Icc)
A Study on Intratumoral Fibrosis and α-SMA Expression in Intrahepatic Cholangiocarcinoma
The aim of this observational study was to understand the prognostic imaging of the degree of intratumoral fibrosis and intratumoral α-SMA levels in patients with intrahepatic cholangiocarcinoma (ICC).
- Trial name
- NCT07479264
- Testing
- No Interventions
- Where
- China
- Volunteers
- 169 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer)
An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients
An exploratory clinical study to evaluate the safety and efficacy of NK cells (combined with standard therapy) in the treatment of solid tumor patients
- Trial name
- CCT-ANK-11 (NCT06284226)
- Testing
- Allogeneic NK（CCT-ANK-11)
- Sponsor
- Beijing Kejing Biotechnology Co., Ltd.
Combined Hepatocellular and Cholangiocarcinoma
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
This is a single arm phase 2 study of Single Tremelimumab with Regular Interval Durvalumab (STRIDE) plus Gemcitabine and Cisplatin (GEMCIS) in locally advanced unresectable/metastatic combined hepatocellular-cholangiocarcinoma…
- Trial name
- NCT06855225
- Testing
- Tremelimumab, Durvalumab, Gemcitabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Mehmet Akce
Hepatocellular Carcinoma, Fibrolamellar Hepatocellular Carcinoma
Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards
The goal of this observational study is to compare the recommendations of the artificial intelligence clinical decision support system 'ADBoard', with the recommendations of physicians by tumor conferences in patients with…
- Conditions
- Hepatocellular Carcinoma, Fibrolamellar Hepatocellular Carcinoma, Cholangiocarcinoma, Perihilar, Intrahepatic Cholangiocarcinoma
- Trial name
- ADBoard (NCT05681949)
- Testing
- ADBoard
- Where
- Germany
- Volunteers
- 1,200 people
- Sponsor
- Charite University, Berlin, Germany